Protheragen Obesity



Ki8751

Cat. No.:	OB0225WX-2413
Appearance:	Solid
Purity:	≥99%
Identity:	Confirmed by NMR, and HPLC.
Size:	5 mg; 10 mg; 25 mg; 50 mg

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	Ki8751 is a potent VEGFR2 inhibitor (IC50: 0.9 nM) that exhibits over 40-fold se lectivity compared to c-Kit, PDGFR-alpha, and FGFR-2.
Synonym	228559-41-9; Ki 8751; Ki-8751; *N*-(2,4-Difluorophenyl)-N'-[4-[(6,7-dimetho xy-4-quinolinyl)oxy]-2-fluorophenyl]urea; 1-(2,4-difluorophenyl)-3-(4-((6,7-dime thoxyquinolin-4-yl)oxy)-2-fluorophenyl)urea; 1-(2,4-difluorophenyl)-3-[4-(6,7-di methoxyquinolin-4-yl)oxy-2-fluorophenyl]urea; 1-(2,4-Difluorophenyl)-3-(4-(6,7-d imethoxyquinolin-4-yl)oxy-2-fluorophenyl)urea; 1-(2,4-difluorophenyl)-3-{4-[(6,7 -dimethoxyquinolin-4-yl)oxy]-2-fluorophenyl}urea; *N*-(2,4-Difluorophenyl)- N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy)-2-fluorophenyl)urea; Urea, *N*-(2,4 -difluorophenyl)-N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy)-2-fluorophenyl)-; MFCD0 9971092; 1-(2,4-difluorophenyl)-3-(4-(6,7-dimethoxyquinolin-4-yloxy)-2-fluorophe nyl)urea; 1-(2,4-Difluoro-phenyl)-3-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro -phenyl]-urea; 1-(2,4-difluorophenyl)-3-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-f luorophenyl]urea; *N*-(2,4-difluorophenyl)-N'-(4-((6,7-dimethoxy-4-quinolyl)oxy)-2-fluorophenyl)urea
CAS No.	228559-41-9
Compound CID	11317348
Formula	$C_{24}H_{18}F_3N_3O_4$
Formula Weight	469.41

Specification

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com

Protheragen Obesity



IUPAC Name	1-(2,4-Difluorophenyl)-3-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-fluorophenyl]urea
InChI	InChI=1S/C24H18F3N3O4/c1-32-22-11-15-20(12-23(22)33-2)28-8-7-21(15)34-14-4-6-19(17(27)10-14)30-24(31)29-18-5-3-13(25)9-16(18)26/h3-12H,1-2H3,(H2,29,30,31)
InChI Key	LFKQSJNCVRGFCC-UHFFFAOYSA-N
SMILES string	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC(=C(C=C3)NC(=O)NC4=C(C=C(C=C4)F)F)F
Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	Ki8751 is employed in oncology research as a potent and selective VEGFR2 tyrosin e kinase inhibitor to investigate the suppression of tumor-induced angiogenesis and the disruption of vascular signaling.

Library Information

Target	c-Kit; PDGFR; VEGFR
Receptor	c-Kit; PDGFR; VEGFR
Pathways	Protein tyrosine kinase
Plate Number	L6700-01
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	47 mg/mL; 100.13 mM
ALogP	4.853
HBA_Count	5
HBD_Count	2
Rotatable Bond	6

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com